Investor Presentaiton
HARMONIE
STUDY
Impressive 83% reduction of RSV-LRTI hospitalizations
confirmed in real world setting
Incidence of RSV-LRTI hospitalization
1.5%
No intervention
n=4,021
83.2%
Relative Risk Reduction
(95% CI: 67.8-92.0;
p<0.001)
0.3%
Beyfortus
n=4,037
sanofi
> RSV is the leading cause of
hospitalization in infants.
> Efficacy of Beyfortus has been
consistent across all studies, and
is maintained for 5 months to cover
the duration of the RSV season
1. SB Drysdale, (2023, May 8-12). A Phase 3 randomized open-label study of nirsevimab (versus no intervention) in preventing hospitalizations due to respiratory syncytial virus (RSV) in infants (HARMONIE) [Oral presentation]. ESPID 2023: Lisbon, Portugal.
26 Vaccines Investor EventView entire presentation